Last reviewed · How we verify
POLYSAN Scientific & Technological Pharmaceutical Company — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
5 Phase 3
5 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Ringer's Solution | Ringer's Solution | marketed | Crystalloid IV fluid / Electrolyte replacement solution | Critical Care / Fluid & Electrolyte Management | ||
| Remaxol | Remaxol | phase 3 | Other | |||
| Placebo enteric-coated tablet | Placebo enteric-coated tablet | phase 3 | ||||
| Cytoflavin® enteric-coated tablet | Cytoflavin® enteric-coated tablet | phase 3 | Metabolic enhancer / Antioxidant combination | Neurology / Metabolic disorders | ||
| Cytoflavin® solution | Cytoflavin® solution | phase 3 | Metabolic activator / Antioxidant combination | Neurology / Critical Care | ||
| Cycloferon | Cycloferon | phase 3 | Other |
Therapeutic area mix
- Other · 5
- Critical Care / Fluid & Electrolyte Management · 1
- Neurology / Critical Care · 1
- Neurology / Metabolic disorders · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for POLYSAN Scientific & Technological Pharmaceutical Company:
- POLYSAN Scientific & Technological Pharmaceutical Company pipeline updates — RSS
- POLYSAN Scientific & Technological Pharmaceutical Company pipeline updates — Atom
- POLYSAN Scientific & Technological Pharmaceutical Company pipeline updates — JSON
Cite this brief
Drug Landscape (2026). POLYSAN Scientific & Technological Pharmaceutical Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/polysan-scientific-technological-pharmaceutical-company. Accessed 2026-05-16.